Temitope Olufunmilayo Lawal

Prof. Temitope Olufunmilayo Lawal


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2012 in Gastroenterology Insights
Verified
Journal Article
Open access
PDF file
BABolanle A. Adeniyi
Bolanle A. Adeniyi
TLTemitope Olufunmilayo Lawal
Temitope Olufunmilayo Lawal
JOJesse A. Otegbayo
Jesse A. Otegbayo
OOOlayiwola A. Oluwasola
Olayiwola A. Oluwasola
GOGeorgina N. Odaibo
Georgina N. Odaibo
AKAderemi O. Kehinde
Aderemi O. Kehinde
Helicobacter pylori consist in a helical shaped Gram-negative bacterium, approximately 3 micrometers long with a diameter of approximately 0.5 micrometers. It has 4-6 flagella. It is microaerophilic and tests positive for oxidase, catalase and urease. With its flagella, the bacterium moves through the stomach lumen and drills into the mucus gel layer of the stomach. In humans, H. pylori have been associated with peptic ulcers, chronic gastritis, duodenitis and stomach cancer. It is widely believed that in the absence of treatment, H. pylori infection, once established in its gastric niche, persists for life. The aim of this research is to study the cultural characteristics and antibiotic susceptibility pattern of H. pylori strains isolated from southwest Nigeria. The cultural characteristics and antibiotic susceptibility pattern of Helicobacter pylori strains isolated from gastric mucosal antral biopsy specimens collected from 43 of 52 dyspepsia patients in the University College Hospital Ibadan, Oyo State, Nigeria, were determined using standard microbiological methods for Helicobacter pylori isolation. The 43 isolates were subjected to 23 different antibiotics and each of the antibiotics demonstrated a variable degree of activity against the isolates. Among the antibiotics to which the organism was most susceptible are: ofloxacin (30 μg) 100% activity, ciprofloxacin (5 μg) 97.67% activity, gentamicin (120 μg) 95.35 activity, amikacin (30 μg), kanamycin (30 μg) and chloramphenicol (30 μg) each 90.70% activity, clarithromycin (15 μg) 93.02, while the less active antibiotics are: augmentin (30 μg) 23.26% active, amoxycillin (25 μg) and metronidazole (50 μg) each 27.91% active and clindamycin (2 mg) 30.23% active. From the result of the antibiotic susceptibility pattern of the strains of the organism, 95.35% of the total isolates are multi drug resistant. Resistance was developed to, among others, augmentin (30 μg), amoxycillin (25 μg), metronidazole (50 μg) and clindamycin (2 mg).

18 July 2025 in Molecules
Verified
Journal Article
Open access
PDF file
NRNishikant Ambadas Raut
Nishikant Ambadas Raut
PKPinal N Kanabar
Pinal N Kanabar
MMMark Maienschein-Cline
Mark Maienschein-Cline
NLNina S. Los
Nina S. Los
ZAZarema Arbieva
Zarema Arbieva
GMGail Mahady
Gail Mahady
The effects of a methanol extract of Nymphaea odorata (MeNO) rhizomes, its fractions and the active compound (methyl gallate, MeG) were investigated in estrogen receptor-positive (ER+) breast cancer cell lines MCF-7 and T47-D:A18, as well as ER-negative line SKBr3. Cell viability and cytotoxicity were determined using CellTiter-Glo® 2.0 assays at concentrations ranging from 1 to 100 μg/mL. Caspase activity and apoptosis were determined using Caspase-Glo® 3/7, Caspase-Glo® 8, and ApoTox-Glo™ triplex assays, as well as qPCR. Total RNA was isolated from MCF-7 cells treated with MeG. RNA-seq libraries were prepared using a Universal Plus mRNASeq kit, and sequencing was performed on a NovaSeq 6000. MeNO inhibited the growth of MCF-7 cells with an IC50 of 14.1 μg/mL, as well as T47-D:A18 (IC50 of 25.6 μg/mL) and SKBr3 cells (IC50 of 35.5 μg/mL). Bioassay-guided fractionation of MeNO in MCF-7 cells identified the active fraction containing one compound, namely methyl gallate (MeG). MeG had an IC50 of 8.6 μg/mL in MCF-7 cells. Transcriptomic analysis of MeG-treated MCF-7 cells showed differential expression of 10,634 genes, with 5643 upregulated and 4991 downregulated (FDR < 0.05). Ingenuity pathway analysis revealed the involvement of 43 canonical pathways, with the top upregulated pathways including apoptosis, autophagy, and the unfolded protein response pathways.

28 March 2017 in African Journal of Microbiology Research
Verified
Journal Article
Open access
PDF file
TLTemitope Olufunmilayo Lawal
Temitope Olufunmilayo Lawal
BTB. Bamiduro Titilayo
B. Bamiduro Titilayo
MJM. Ofonmbuk Jumbo
M. Ofonmbuk Jumbo
OTO. Elufioye Taiwo
O. Elufioye Taiwo
ABA. Adeniyi Bolanle
A. Adeniyi Bolanle
BGB. Mahady Gail
B. Mahady Gail
The development of effective and less toxic antimicrobial agents is required for the treatment of respiratory tract infections. This study was carried out to evaluate the phytochemical and antibacterial activities of Anogeissus leiocarpus (DC.) (Guill. & Perr.) and Terminalia glaucescens (Planch. ex Benth.) against non-tuberculous mycobacteria species. The methanol, dichloromethane and aqueous extracts were screened against five (5) non-tuberculosis mycobacteria (NTM) species by agar diffusion method. Minimum inhibitory concentration (MIC) was determined by agar dilution method while bactericidal studies were done by viable count technique. The methanol and aqueous extracts were active against all the test organisms with zones of inhibition ranging from 10±0.0 to 25±0.5 mm. The MIC and MBC range from 0.3125 to 2.5 and 1.25 to 10 mg/mL, respectively. Bactericidal activities of aqueous extracts against Mycobacterium smegmatis ATCC 19420 revealed a drastic dose-dependent decline in the surviving population after 6 h of exposure accompanied by a total (100%) kill after 24 h of exposure. The antimicrobial activities demonstrated by these plants suggest the presence of therapeutically important antimycobacterial compounds and thus justify as well as support the use of these medicinal plants for the treatment of respiratory tract infections. Key words: Anogeissus leiocarpus (DC.) (Guill. & Perr.), Terminalia glaucescens (Planch. ex Benth.), antibacterial, nontuberculous mycobacteria species, bactericidal, in vitro.

6 November 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
TLTemitope Olufunmilayo Lawal
Temitope Olufunmilayo Lawal
BABolanle Alake C. Adeniyi
Bolanle Alake C. Adeniyi
GMGail Mahady
Gail Mahady
Background and Objectives: Vitamins A and D have been reported to improve cancer outcomes. In this work, we reviewed recent meta-analyses, preclinical, and transcriptomics data for these vitamins and combinations for breast and colon cancers. Methods: Searches for meta-analyses, preclinical, and transcriptomic data for vitamins A and D in breast and colorectal cancers were conducted using electronic databases from June 2012 to May 2025. Studies describing the effects of vitamin A and D levels (through diet, supplementation, and serum concentrations) on the risk, prognosis, metastasis, and survival rates of breast and colon cancer patients, and the doses needed to achieve these endpoints, were included. Preclinical and transcriptomics studies investigating combinations of vitamins A and D were also reviewed. Results: The reviewed studies showed an inverse correlation between vitamin A intake and the risk and survival rates of breast cancers. Sufficient vitamin D3 levels were associated with improved survival outcomes, lower tumor grades, and less ER- or triple-negative breast cancers. For colorectal cancers, meta-analyses showed conflicting results for vitamin A, but clear evidence that vitamin D reduced both risk and mortality. Preclinical and transcriptomics studies provide compelling evidence that vitamins A and D combinations may be more effective for the prevention and treatment of breast and colon cancers, due to their significant synergistic effects and the larger number of cancer-signaling pathways impacted. Conclusions: Vitamins A and D reduce breast and colorectal cancer incidence, risk and mortality through multiple mechanisms of action, and offer significant potential as therapeutic and chemopreventative agents.

11 June 2014 in African Journal of Microbiology Research
Verified
Journal Article
Open access
TLTemitope Olufunmilayo Lawal
Temitope Olufunmilayo Lawal
EAE. Mbanu Augustine
E. Mbanu Augustine
ABA. Adeniyi Bolanle
A. Adeniyi Bolanle
The plants Ceiba pentandra (L.) Gaertn. [Malvaceae previously Bombacaceae] and Cordia sebestena Linn. [Boraginaceae] used in this study were selected to investigate and justify their local use in the treatment of cough, catarrh, sore throat, pneumonia and tuberculosis, all of which are associated with respiratory tract infections. The antimycobacterial activities of these plants were investigated in Mycobacterium fortuitum ATCC 684, Mycobacterium smegmatis ATCC 19420, Mycobacterium abscessus and Mycobacterium phlei ATCC 19240. The agar cup diffusion method was used for the antimycobacterial screening at concentrations of 10, 20, 100 and 200 mg/ml while the agar dilution method was used for the determination of the minimum inhibitory concentration (MIC). Phytochemical screening revealed the presence of tannins, cardenolides, alkaloids, anthraquinones and saponins in all the plant samples except in C. sebestena leaf in which saponins and anthraquinones were absent. The inhibitory activity of methanolic extracts of the stem barks of C. pentandra and C. sebestena on the test organisms was dose-dependent. The MIC and the minimum bactericidal concentration (MBC) of the extracts ranged from 20 - 200 and 40 - 600 mg/ml, respectively. The results obtained in this study justify the ethnomedicinal use of the plants in conditions associated with respiratory tract infections. Key words: Inhibitory activities, Ceiba pentandra (L.) Gaertn., Cordia sebestena Linn., rapidly growing mycobacteria, in vitro.

7 April 2026 in Innovative Medicines & Omics
Verified
Journal Article
Open access
PDF file
TLTemitope Olufunmilayo Lawal
Temitope Olufunmilayo Lawal
PKPinal N Kanabar
Pinal N Kanabar
NLNina S. Los
Nina S. Los
SPShitalben M. Patel
Shitalben M. Patel
MMMark Maienschein-Cline
Mark Maienschein-Cline
GMGail Mahady
Gail Mahady
Breast cancer remains the most diagnosed cancer among women worldwide, and its prevalence continues to increase annually. Previously, we reported that ellagic acid (EA), a compound isolated from Terminalia leiocarpa (DC.) Baill., a plant used in Nigerian traditional medicine, inhibited the proliferation of cultured human MCF-7 breast cancer cells. EA is a pharmacologically active polyphenolic compound with antioxidant, anti-inflammatory, and anti-estrogenic activities. In this work, we investigated the effects of EA on the transcriptome of MCF-7 cells using next-generation sequencing. After EA treatment, MCF-7 cells were harvested, and total RNA was isolated and used to prepare RNA sequencing libraries. Sequencing was performed using NovaSeq 6000. The results showed that EA significantly altered gene expression patterns in MCF-7 cells. Bioinformatic analysis of the sequencing data revealed that 4,848 transcripts were differentially expressed, with 2,180 upregulated genes and 2,668 downregulated genes (q ≤ 0.01). Ingenuity Pathway Analysis indicated that EA-induced expression changes mapped to 98 canonical pathways, including upregulation of apoptosis signaling pathways and downregulation of estrogen signaling and estrogen-dependent breast cancer signaling pathways (q ≤ 0.05). Furthermore, EA downregulated gene expression in the epithelial-to-mesenchymal transition (EMT) canonical pathway, such as PRRX1/2, TGF, TWIST1, and VIM. These data indicate that EA has multiple mechanisms of action in MCF-7 cells, including the induction of apoptosis and the reduction of both estrogen and EMT signaling. Thus, with further research, EA may serve as an inexpensive, safe, and effective treatment for breast cancer and metastatic diseases.